Late Stage Investors & VC Firms in Global
909 firms in this list, with a median first check of $1M. 222 of them lead rounds. Generated from verified public data and updated continuously.
Sectoral Asset Management
MontrealSeries A–Late Stage
9 people
Cabra VC
LimassolSeed–Late Stage
5 people
Access Biotechnology
New York CitySeed–Late Stage
2 people
Checkmate Capital Group LLC
PasadenaSeed–Late Stage
7 people
FootPrint Coalition
Los AngelesSeed–Late Stage$50K – $1M
3 people
HIP Investor
San FranciscoLate Stage
12 people
ICU Ventures
KyivSeed–Late Stage$200K – $5M
3 people
Oquirrh Ventures
Salt Lake CityGrowth–Late Stage$10M – $50M
6 people
Phoenix Contact Innovation Ventures
BlombergSeed–Late Stage$108K – $2.7M
6 people
20/20 HealthCare Partners LLC
AuburndaleSeed–Late Stage
7 people
Clal Biotechnology Industries
Tel AvivSeed–Late Stage
9 people
Reaction
Seed–Late Stage
11 people
H Venture Partners
CincinnatiSeed–Late Stage$250K – $5M
2 people
Ring Capital
ParisPre-Seed–Late Stage$540K – $16.2M
2 people
Fresenius Medical Care Ventures
Bad HomburgSeed–Late Stage
7 people
Aliment Capital
Los AngelesGrowth–Late Stage$3M – $5M
3 people
Utiliti Group
SydneySeed–Late Stage
KIC Ventures
Fort LauderdaleSeed–Late Stage
10 people
MAIF Avenir
ParisSeed–Late Stage$10.8M
7 people
Veronorte
MedellínSeed–Late Stage
6 people
tokentus investment AG
FrankfurtGrowth–Late Stage
11 people
Waarde Capital
CapellenPre-Seed–Late Stage$15M
5 people
HBM Healthcare Investments
ZugGrowth–Late Stage
7 people
Titan Capital Partners
Palm BeachGrowth–Late Stage
7 people
Related lists
Investors & VC Firms in North America (13845)Investors & VC Firms in United States (12980)Seed Investors & VC Firms (10975)Series A Investors & VC Firms (8160)Pre-Seed Investors & VC Firms (5955)Seed Investors & VC Firms in North America (5705)Investors & VC Firms in Europe (5528)Seed Investors & VC Firms in United States (5128)Growth Investors & VC Firms (4870)Series A Investors & VC Firms in North America (4605)
Data sourced from public filings and firms' own websites — see our methodology.
















































































